Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.

Jianming HeHeather BerringerBart HeegHaoyao RuanTobias KampfenkelHarikumaran R DwarakanathanStephen JohnstonJoão MendesAnnette LamSacheeta BathijaEric Mackay

Published in: Advances in therapy (2022)

NCT03180736; NCT02136134, NCT01998971.

Keyphrases

multiple myeloma
healthcare
palliative care
low dose
high dose
quality improvement
acute lymphoblastic leukemia
acute myeloid leukemia
replacement therapy